BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Davis SM, Davidov D, Kristjansson AL, Zullig K, Baus A, Fisher M. Qualitative case study of needle exchange programs in the Central Appalachian region of the United States. PLoS One 2018;13:e0205466. [PMID: 30312333 DOI: 10.1371/journal.pone.0205466] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
2 Schwambach KH, Farias MR, Neto GB, Blatt CR. Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data. Value Health Reg Issues 2020;23:49-54. [PMID: 32702649 DOI: 10.1016/j.vhri.2020.05.002] [Reference Citation Analysis]
3 Skill NJ, Butler J, O’brien DC, Kays JK, Kubal CA, Liangpunsakul S, Ninad N, Maluccio MA. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma. Transplantation Proceedings 2019;51:1907-12. [DOI: 10.1016/j.transproceed.2019.04.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Wurcel AG, Burke DJ, Wang JJ, Engle B, Noonan K, Knox TA, Kim AY, Linas BP. The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis. J Urban Health 2018;95:467-73. [PMID: 30027427 DOI: 10.1007/s11524-018-0277-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Quinn K, Fong C, Guarino H, Mateu-Gelabert P. Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City. Drug Alcohol Depend 2019;194:453-9. [PMID: 30503906 DOI: 10.1016/j.drugalcdep.2018.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL, Alavian SM. The role of the Primary Healthcare Network in Iran in hepatitis C virus elimination by 2030. Journal of Virus Eradication 2018;4:186-8. [DOI: 10.1016/s2055-6640(20)30265-x] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. J Viral Hepat 2021;28:728-38. [PMID: 33555102 DOI: 10.1111/jvh.13479] [Reference Citation Analysis]
8 Negro F. Expanded benefits of curing the extrahepatic manifestations of HCV infection. Gut 2018;67:1917-9. [PMID: 29871969 DOI: 10.1136/gutjnl-2018-316578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Younossi ZM. Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply. Aliment Pharmacol Ther 2018;47:537-8. [PMID: 29341278 DOI: 10.1111/apt.14481] [Reference Citation Analysis]
10 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
11 Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35. [PMID: 30218908 DOI: 10.1016/j.ejmech.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Jung J, Feldman R, Kalidindi Y, Riley T 3rd. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries. JAMA Netw Open 2020;3:e208081. [PMID: 32602909 DOI: 10.1001/jamanetworkopen.2020.8081] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-gómez M, Anstee QM, Schattenberg JM. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology 2019;17:2085-2092.e1. [DOI: 10.1016/j.cgh.2018.12.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
14 Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis 2018;66:1742-50. [PMID: 29272349 DOI: 10.1093/cid/cix1106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
15 Younossi ZM, Henry L, P. Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim Y, Dan YY, Yu M, Stepanova M. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644-53. [DOI: 10.1111/apt.15131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
16 Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of Virus Eradication 2019;5:116-21. [DOI: 10.1016/s2055-6640(20)30053-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Yuasa A, Yonemoto N, Demiya S, Foellscher C, Ikeda S. Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries. Pharmacoecon Open 2021;5:57-69. [PMID: 33108616 DOI: 10.1007/s41669-020-00235-6] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology 2018;67:2449-59. [PMID: 29181853 DOI: 10.1002/hep.29685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
19 Thedja MD, Wibowo DP, El-Khobar KE, Ie SI, Setiawan L, Murti IS, Muljono DH; Turyadi. Improving Linkage to Care of Hepatitis C: Clinical Validation of GeneXpert® HCV Viral Load Point-of-Care Assay in Indonesia. Am J Trop Med Hyg 2021:tpmd201588. [PMID: 33999849 DOI: 10.4269/ajtmh.20-1588] [Reference Citation Analysis]
20 Zhao Q, Jiang S, Li M, Yao L, Ma X, Li M, Wang C, Pan Y, Zhao H, Li B. Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. Medicine (Baltimore) 2020;99:e22005. [PMID: 32899048 DOI: 10.1097/MD.0000000000022005] [Reference Citation Analysis]
21 Wong WW, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A, Feng Z, Feld JJ, Mitsakakis N, Powis J, Krahn M. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. Value in Health 2022;25:247-56. [DOI: 10.1016/j.jval.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang J, Huang Z, Liu X, Wu C, Zhou W, Ye P, Stalin A, Lu S, Tan Y, Wu Z, Fan X, Zhang X, Wang M, Li B, Cheng G, Mou Y, Wu J, Wan S. Exploring the Multicomponent Synergy Mechanism of Yinzhihuang Granule in Inhibiting Inflammation-Cancer Transformation of Hepar Based on Integrated Bioinformatics and Network Pharmacology. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/6213865] [Reference Citation Analysis]
23 Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020;99:e21270. [PMID: 32791706 DOI: 10.1097/MD.0000000000021270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Nersesov A, Gusmanov A, Crape B, Junusbekova G, Berkinbayev S, Jumabayeva A, Kaibullayeva J, Madenova S, Novitskaya M, Nazarova M, Gaipov A, Ashimkhanova A, Kadyrzhanuly K, Atageldiyeva K, Vento S, Issanov A. Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan. PLoS One 2021;16:e0261155. [PMID: 34914773 DOI: 10.1371/journal.pone.0261155] [Reference Citation Analysis]
25 Breton S, van Vlymen J, Xia S, Holden RR, Phelan R, Sagan SM, Jaeger M. A survey of medication preparation and administration practices among members of the Canadian Anesthesiologists’ Society. Can J Anesth/J Can Anesth 2018;65:1100-9. [DOI: 10.1007/s12630-018-1164-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Schreiner AD, Bian J, Zhang J, Haulsee ZM, Marsden J, Durkalski-Mauldin V, Mauldin PD, Moran WP, Rockey DC. The Association of Abnormal Liver Tests with Hepatitis C Testing in Primary Care. Am J Med 2020;133:214-221.e1. [PMID: 31369723 DOI: 10.1016/j.amjmed.2019.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Feng JY, Ray AS. HCV RdRp, sofosbuvir and beyond. Enzymes 2021;49:63-82. [PMID: 34696839 DOI: 10.1016/bs.enz.2021.06.003] [Reference Citation Analysis]
28 Falade-Nwulia O, Ward KM, McCormick S, Mehta SH, Pitts SR, Katz S, Chander G, Thomas DL, Sulkowski M, Latkin CA. Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. J Viral Hepat 2020;27:663-70. [PMID: 32045086 DOI: 10.1111/jvh.13274] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Schwander B, Feldstein J, Sulo S, Gonzalez L, ElShishiney G, Hassany M. Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program. Infect Dis Ther 2022. [PMID: 35451742 DOI: 10.1007/s40121-022-00631-x] [Reference Citation Analysis]
30 Beheshti D. Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin. Health Econ 2019;28:1449-61. [PMID: 31715653 DOI: 10.1002/hec.3944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Kinh N, Lai CL, Yuen MF, Chan HL, Lai W. The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. Liver Int. 2018;38:1179-1187. [PMID: 29197140 DOI: 10.1111/liv.13650] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
33 Byenfeldt M, Elvin A, Fransson P. Influence of Probe Pressure on Ultrasound-Based Shear Wave Elastography of the Liver Using Comb-Push 2-D Technology. Ultrasound Med Biol 2019;45:411-28. [PMID: 30401508 DOI: 10.1016/j.ultrasmedbio.2018.09.023] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Buti M, Domínguez-Hernández R, Casado MÁ, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13:e0208036. [PMID: 30485377 DOI: 10.1371/journal.pone.0208036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
35 Behzadifar M, Gorji HA, Rezapour A, Behzadifar M, Bragazzi NL. The role of insurance providers in supporting treatment and management of hepatitis C patients. BMC Health Serv Res 2019;19:25. [PMID: 30630488 DOI: 10.1186/s12913-019-3869-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Cacoub P, Bourliere M, Asselah T, De Ledinghen V, Mathurin P, Hézode C, Henry L, Stepanova M, Younossi ZM. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. Value Health 2018;21:1218-25. [PMID: 30314623 DOI: 10.1016/j.jval.2018.01.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]